The company said it has decided to stop distributing its once-daily basal insulin Tresiba (insulin degludec) in Germany - Europe's largest pharmaceutical market - in the wake of a "negative ...
Novo Nordisk said it will cut the list prices in the U.S. of two of its insulin drugs, Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price ...
Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback